Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
Pfizer has officially closed its acquisition of Metsera for about $9.2 billion, ending a high-profile bidding war with Novo Nordisk.
The deal includes $7 billion upfront and up to $2.2 billion in contingent value rights (CVRs) tied to clinical and regulatory milestones.
Metsera's board chose Pfizer over Novo Nordisk due to lower antitrust and regulatory risks, as Novo's bid faced potential delays and legal hurdles.
Metsera is now a wholly owned subsidiary of Pfizer, with its obesity drug candidates, including MET-097 and MET-233, expected to reach the market as early as 2028.
Pfizer's acquisition positions it as a major player in the rapidly growing obesity drug market, competing with Novo Nordisk and Eli Lilly.